BR112016016469A2 - Composição farmacêutica líquida, composição parenteral, processo para produção das referidas composições farmacêuticas e kit de partes - Google Patents

Composição farmacêutica líquida, composição parenteral, processo para produção das referidas composições farmacêuticas e kit de partes

Info

Publication number
BR112016016469A2
BR112016016469A2 BR112016016469A BR112016016469A BR112016016469A2 BR 112016016469 A2 BR112016016469 A2 BR 112016016469A2 BR 112016016469 A BR112016016469 A BR 112016016469A BR 112016016469 A BR112016016469 A BR 112016016469A BR 112016016469 A2 BR112016016469 A2 BR 112016016469A2
Authority
BR
Brazil
Prior art keywords
composition
production
kit
parts
pharmaceutical compositions
Prior art date
Application number
BR112016016469A
Other languages
English (en)
Other versions
BR112016016469A8 (pt
BR112016016469B1 (pt
Inventor
HÄUSLER Franz
Scheidl Helmut
Wagner Daniel
Original Assignee
Gebro Holding Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gebro Holding Gmbh filed Critical Gebro Holding Gmbh
Publication of BR112016016469A2 publication Critical patent/BR112016016469A2/pt
Publication of BR112016016469A8 publication Critical patent/BR112016016469A8/pt
Publication of BR112016016469B1 publication Critical patent/BR112016016469B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01M—PROCESSES OR MEANS, e.g. BATTERIES, FOR THE DIRECT CONVERSION OF CHEMICAL ENERGY INTO ELECTRICAL ENERGY
    • H01M10/00—Secondary cells; Manufacture thereof
    • H01M10/42—Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
    • H01M10/425—Structural combination with electronic components, e.g. electronic circuits integrated to the outside of the casing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Abstract

COMPOSIÇÃO FARMACÊUTICA LÍQUIDA, COMPOSIÇÃO PARENTERAL, PROCESSO PARA PRODUÇÃO DAS REFERIDAS COMPOSIÇÕES FARMACÊUTICAS E KIT DE PARTES. A presente invenção refere-se a uma composição farmacêutica líquida, particularmente, como concentrado para produção e uma solução de infusão, que contém alprostadil como substância ativa, dissolvido em um solvente não aquoso, contendo pelo menos um ácido ou uma substância que atua como ácido ou como doador de prótons, como estabilizador para a substância ativa.
BR112016016469-5A 2014-01-30 2015-01-29 Composição farmacêutica líquida, composição parenteral, processo para produção das referidas composições farmacêuticas e kit de partes BR112016016469B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA50063/2014A AT515356B1 (de) 2014-01-30 2014-01-30 Stabile alkoholische Lösung von Alprostadil
ATA50063/2014 2014-01-30
PCT/AT2015/050029 WO2015113094A1 (de) 2014-01-30 2015-01-29 Stabile alkoholische lösung von alprostadil

Publications (3)

Publication Number Publication Date
BR112016016469A2 true BR112016016469A2 (pt) 2017-08-08
BR112016016469A8 BR112016016469A8 (pt) 2018-01-30
BR112016016469B1 BR112016016469B1 (pt) 2021-09-28

Family

ID=53432896

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016016469-5A BR112016016469B1 (pt) 2014-01-30 2015-01-29 Composição farmacêutica líquida, composição parenteral, processo para produção das referidas composições farmacêuticas e kit de partes

Country Status (7)

Country Link
EP (2) EP3395367A1 (pt)
JP (1) JP2017507172A (pt)
AT (1) AT515356B1 (pt)
BR (1) BR112016016469B1 (pt)
MX (1) MX369244B (pt)
RU (1) RU2016135034A (pt)
WO (1) WO2015113094A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2695068C1 (ru) * 2018-06-26 2019-07-19 Общество с ограниченной ответственностью "Гурус БиоФарм" Средство для лечения хронических облитерирующих заболеваний периферических сосудов на основе простагландина
EE05864B1 (et) * 2021-12-22 2024-02-15 Aktsiaselts Kevelt 3-hüdroksütsüklopentoonitsüklit sisaldava ühendi kompositsioon ja meetod selle stabiliseerimiseks

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927197A (en) * 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
JPS6019734B2 (ja) * 1977-05-12 1985-05-17 三共株式会社 安定なプロスタグランジンｅ類製剤の製法
ZA831186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
JPH0737389B2 (ja) * 1989-08-29 1995-04-26 久光製薬株式会社 プロスタグランジンｅ１含有の軟膏剤
KR100453803B1 (ko) 1999-07-29 2004-10-20 환인제약 주식회사 알프로스타딜 함유 외용제 조성물
UA78432C2 (uk) * 2005-08-09 2007-03-15 Закрите Акціонерне Товариство Науково-Виробничий Центр "Борщагівський Хіміко-Фармацевтичний Завод" Засіб для лікування ішемічних та гнійно-некротичних уражень нижніх кінцівок при діабетичних ангіопатіях, який містить алпростадил
WO2009093650A1 (ja) * 2008-01-24 2009-07-30 Techno Guard Co. Ltd. プロスタグランジン含有脂肪乳剤およびその製造方法
EP2692360A4 (en) * 2011-03-31 2014-10-29 Fujifilm Corp FATTY EMULSION CONTAINING PROSTAGLANDIN
CN102351767B (zh) * 2011-09-20 2013-03-06 海南美兰史克制药有限公司 一种前列地尔化合物及其制法
CN102688203A (zh) 2012-06-06 2012-09-26 杭州澳亚生物技术有限公司 一种前列地尔冻干粉针剂及其制备方法
CN103110579B (zh) * 2013-02-20 2014-12-10 北京德立福瑞医药科技有限公司 前列地尔注射剂

Also Published As

Publication number Publication date
JP2017507172A (ja) 2017-03-16
MX2016009458A (es) 2017-04-25
EP3099330B1 (de) 2018-03-14
EP3395367A1 (de) 2018-10-31
RU2016135034A (ru) 2018-03-01
BR112016016469A8 (pt) 2018-01-30
AT515356B1 (de) 2015-11-15
WO2015113094A1 (de) 2015-08-06
EP3099330A1 (de) 2016-12-07
AT515356A1 (de) 2015-08-15
RU2016135034A3 (pt) 2018-05-11
MX369244B (es) 2019-11-01
BR112016016469B1 (pt) 2021-09-28

Similar Documents

Publication Publication Date Title
GT201400279A (es) Jeringa
BR112017010481A2 (pt) agonista parcial de receptor de insulina, composição, dímeros de análogo de insulina e de insulina, método para tratar diabetes, usos de um agonista parcial de receptor de insulina e de um composto, e, composto.
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina
BR112014032990A2 (pt) seringa
BR112016014020A2 (pt) Compostos moduladores de tetra-hidropiridopirazinas de gpr6, seus sais e os usos dos mesmos
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
DOP2016000210A (es) Proceso para producir una solución inyectable de noradrenalina de baja concentración, estable
BR112018005194A2 (pt) processo de composto antifúngico
BR112017027137A2 (pt) reguladores de nrf2
BR112013019026A2 (pt) formulações farmacêuticas incluindo um composto amina
EA201890704A1 (ru) Способы получения стабильных терапевтических составов в апротонных полярных растворителях
BR112016016578A2 (pt) Insulina de ação prolongada e uso daanálogo de insulina, polinucleotídeo, vetor de expressão, transformante, insulina de ação prolongada bem como seu método de preparação e formulação da mesma, conjugado, e uso do mesmo mesma
BR112017013691A2 (pt) composição compreendendo um polímero em multiestágio, seu método de preparação e seu uso
ECSP14013302A (es) Composiciones de yodo-povidona estable
BR112017006352A2 (pt) solvente para soluções de triamida tiofosfórica ou diciandiamida e métodos relacionados
BR112017011542A2 (pt) produção de ácido oleico em levedura
CL2015003738A1 (es) Formulación líquida estable de amg-416 (velcalcetida)
CL2017000818A1 (es) Derivativos de benzotiofenil substituidos como agonistas gpr40 para el tratamiento de diabetes tipo ii
BR112017005821A2 (pt) formulação aquosa, método para a preparação de uma formulação aquosa, conjunto, método para a preparação de uma composição farmacêutica, composição farmacêutica e método para quimicamente estabilizar uma formulação aquosa
EA201790570A1 (ru) Модуляторы р2х7
GT201600066A (es) Composiciones y métodos para inhibir la expresión del gen alas1
BR112017009289A2 (pt) métodos de administrar composições de amantadina
UY36209A (es) Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen
CR20140473A (es) Compuestos de pirazol como inhibidores de sglt1
BR112018071519A2 (pt) técnicas para avaliação comparativa de estratégias de pareamento em um sistema de centro de contato

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/01/2015, OBSERVADAS AS CONDICOES LEGAIS.